Other Publications Referenced in Amarin’s Investor Communications

Wang X, Verma S, Mason RP, Bhatt DL. The road to approval: a perspective on the role of icosapent ethyl in cardiovascular risk reduction. Curr Diabetes Rep. 2020;20:65. https://link.springer.com/content/pdf/10.1007/s11892-020-01343-7.pdf

Radenkovic D, Olshansky B, Bhatt D. New insights into icosapent ethyl for patients with residual cardiovascular risk. EMJ Cardiol. 2020;8:34-40. https://www.emjreviews.com/cardiology/symposium/new-insights-into-icosapent-ethyl-for-patients-with-residual-cardiovascular-risk/

Bhatt DL. Mechanisms of action, efficacy, and safety of icosapent ethyl: from bench to bedside. Eur Heart J. 2020;22(Supplement J):J1-J2. https://doi.org/10.1093/eurheartj/suaa114

O’Connell TD, Mason RP, Budoff MJ, Navar AM, Shearer GC. Mechanistic insights into cardiovascular protection for omega-3 fatty acids and their bioactive lipid metabolites. Eur Heart J. 2020;22(Supplement J):J3-J20. https://doi.org/10.1093/eurheartj/suaa115

Parhofer KG, Chapman MJ, Nordestgaard BG. Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap. Eur Heart J. 2020;22(Supplement J):J21-J33. https://doi.org/10.1093/eurheartj/suaa116

Olshansky B, Chung MK, Budoff MJ, et al. Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies. Eur Heart J. 2020;22(Supplement J):J34-J48. https://doi.org/10.1093/eurheartj/suaa117

Ferrari R, Censi S, Cimaglia P. The journey of omega-3 fatty acids in cardiovascular medicine. Eur Heart J. 2020;22(Supplement J):J49-J53. https://doi.org/10.1093/eurheartj/suaa118

Toth PP, Shah PK, Lepor NE. Targeting hypertriglyceridemia to mitigate cardiovascular risk: a review. Am J Prevent Cardiol. 2020; epub ahead of print. https://www.sciencedirect.com/science/article/pii/S2666667720300866